Patients who have a decrease of 1 to 4 points on the ALSFRS-R score during the 12-weeks observation period prior to screening and enrollment
Patients of less than 2 years after the diagnosis of ALS.
Patients without respiratory symptoms (orthopnea, dyspnea)
Capable of giving signed informed consent
You may not be if
Patients who have developed respiratory failure necessitating ventilation
Patients who have developed unsafe swallowing necessitating enteral feeding tube insertion
Patients with other neurodegenerative disease such as Parkinson's disease and significant mental health illness
Patients with certain concomitant diseases which may affect the assessment of safety/efficacy i.e. malignancy within the last 5 years, congestive heart disease, liver disease, kidney failure, bleeding disorders and other autoimmune diseases etc.
Pregnant, lactating, and probably pregnant patients.
Patients taking vitamin E tocopherol or tocotrienols supplements within 1 month from screening and randomisation.
Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.
Women of child bearing potential or nursing mother, unless they are willing to practice effective contraceptive measures.
